Woodcock: Use Of Real-World Evidence Still Brings ‘A Lot Of Problems’
US FDA acting commissioner Janet Woodcock says the use of real-world evidence in product reviews will be slower than many of its supporters are hoping because there are a number of problems that still need to be addressed.
You may also be interested in...
The FDA’s outgoing second-in-command, Amy Abernethy, is confident she’s leaving the agency in good hands but plans to continue to advocate for patients by focusing on areas such as trial design and use of real-world evidence. In this interview with Medtech Insight, Abernethy also talks about the work she put in to make sure there was a change in IT culture at the agency, among other topics.
The US FDA’s device center has reassigned staff and let some product reviews fall to the back burner while it grapples with a crush of new product applications tied to COVID-19.
US regulators say Verily’s Study Watch – meant to be used in Parkinson’s trials – doesn’t collect data needed to assess whether a patient is truly benefitting from a drug.